PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Category	Detail
Condition	Ovarian cancer with brain metastases
Key Mechanisms	PD-1 inhibitors block PD-L1 interaction, enhancing T-cell activation and immune response against tumor cells.
Target Population	Ovarian cancer patients with brain metastases, particularly those with single brain metastases.
Care Setting	Oncology, including surgical, radiotherapy, and chemotherapy settings.

Single brain metastasis patient achieved complete response after comprehensive treatment.
Multiple brain metastases patient showed short-term efficacy but died due to complications.
Higher expression of immune markers in brain metastases suggests enhanced immune activity.
Gene testing confirmed homologous recombination repair deficiency in the single metastasis patient.
Combination therapy may provide new treatment options for specific ovarian cancer patients.

Consider PD-1 inhibitors in combination with chemotherapy and targeted therapy for treatment.

Regular imaging and tumor marker assessments to monitor treatment response and recurrence.

Patients with multiple brain metastases have a poor prognosis and higher risk of complications.

Ovarian cancer patients with brain metastases.

Comprehensive treatment including surgery, radiotherapy, chemotherapy, and PD-1 inhibitors may improve outcomes in select patients.

Evaluate immune microenvironment characteristics to predict immunotherapy efficacy.
Incorporate gene testing for homologous recombination repair deficiency in treatment planning.

Clinical Scorecard: Combination of PD-1 Inhibitor and Chemoradiotherapy in Ovarian Cancer Patients with Brain Metastases: A Case Study